[PAH and many other indications. Old and new endothelin receptor antagonists.].
Schmitz
Jens
J
Universität Würzburg, Würzburg.
Holzgrabe
Ulrike
U
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D002986:Clinical Trials as Topic; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000502:physiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D010455:Peptides; D013449:Sulfonamides; D000077300:Bosentan